CClinicalTrials.gg
CompletedNCT06369805Updated Apr 17, 2024

EVALUATION OF BLOOD BIOMARKER-BASED DIAGNOSTIC AID IN OUTPATIENTS SUFFERING FROM DEPRESSION

An observational study in Depressive Disorder, Bipolar Disorder and Bipolar Depression, sponsored by Les Toises - Psychiatry and Psychotherapy Center. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Les Toises - Psychiatry and Psychotherapy Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
307
Ages
18 Years and older
Sex
All
01

Study summary

This is an observational (non-interventional) study, carried out in an outpatient setting, which involves a blood sampling. The primary objective of this study is to confirm the association between the EDIT-B® editing signature and early unipolar or bipolar differentiation. Results of this research may provide an aid to early diagnosis and guide clinical practice towards individualized treatment.

02

Conditions studied

  • Depressive Disorder
  • Bipolar Disorder
  • Bipolar Depression
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,643 are open to participants now.

This study's enrollment of 307 is above the median of 160 across 1,084 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Les Toises - Psychiatry and Psychotherapy Center is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult outpatients suffering from depression and/or bipolar disorders

Inclusion criteria

Adult outpatients suffering from depression and/or bipolar disorders who gave their written informed consent to participate in the present study

Exclusion criteria

Exclusion Criteria:

Any patient without capacity of discernment or with harmful use of psychoactive substances

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
307 participants (actual)
Patient registry
No

Groups and cohorts

  • one group

    Other: there is no intervention

Interventions

  • Otherthere is no intervention

    there is no intervention

06

What researchers measure

Primary outcomes

  1. Psychiatric symptomatology

    self- and hetero-psychiatric scales

    Time frame: Once

07

Study locations

1 site
  • Les Toises - Psychiatry and Psychotherapy Center
    Lausanne, 1005, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06369805
Lead sponsor
Les Toises - Psychiatry and Psychotherapy Center
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Jun 2, 2021
Primary completion
Nov 17, 2022
Completion
Nov 17, 2022
Last update
Apr 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion